Anti-ICAM-1 monoclonal antibody

Drug Profile

Anti-ICAM-1 monoclonal antibody

Alternative Names: Anti-CD54 monoclonal antibody; Anti-ICAM-1

Latest Information Update: 11 Sep 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Coronary disorders; Diabetes mellitus; Rheumatoid arthritis; Thrombosis; Transplant rejection

Most Recent Events

  • 14 Jun 2001 No-Development-Reported for Transplant rejection in Germany (Unknown route)
  • 14 Jun 2001 No-Development-Reported for Transplant rejection in Japan (Unknown route)
  • 15 Apr 1997 No-Development-Reported for Diabetes mellitus in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top